Survival Analysis of Stage Ⅳ Metastatic Gastric Cancer Patients Treated with HangAm-Plus

Objective：To evaluate the efficacy of HangAm-Plus（HAP）on stageⅣmetastatic gastric cancer by analyzing the treated patients’overall survival outcome.Methods：Following the study eligibility,overall survival and one year survival rate of 44 stageⅣmetastatic gastric cancer patients who visited EastWest...

Full description

Saved in:
Bibliographic Details
Published in:Chinese journal of integrative medicine 2014, Vol.20 (1), p.49-55
Main Authors: Park, Jae-Woo, Yoon, Jeungwon, Cho, Chong-Kwan, Lee, Yeon-Weol, Yoo, Hwa-Seung
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Clinical Experience
Drugs, Chinese Herbal - adverse effects
Drugs, Chinese Herbal - therapeutic use
Female
HAP
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Survival Analysis
Young Adult
患者
生存分析
综合治疗
联合治疗
胃癌
舞台
转移性
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c370t-9821e673ecfa66665d48c1fd596e9aaafc8ecce12d8113d8903a011a7db161153
cites cdi_FETCH-LOGICAL-c370t-9821e673ecfa66665d48c1fd596e9aaafc8ecce12d8113d8903a011a7db161153
container_end_page 55
container_issue 1
container_start_page 49
container_title Chinese journal of integrative medicine
container_volume 20
creator Park, Jae-Woo
Yoon, Jeungwon
Cho, Chong-Kwan
Lee, Yeon-Weol
Yoo, Hwa-Seung
description Objective：To evaluate the efficacy of HangAm-Plus（HAP）on stageⅣmetastatic gastric cancer by analyzing the treated patients’overall survival outcome.Methods：Following the study eligibility,overall survival and one year survival rate of 44 stageⅣmetastatic gastric cancer patients who visited EastWest Cancer Center（EWCC）were analyzed.The study consisted of two arms：HAP treatment only（n=18）and combined treatment of concurrent conventional chemotherapy and HAP（n=26）.Patient characteristics by gender,age,surgical intervention,Eastern Cooperative Oncology Group（ECOG）score,treatment duration（〈4 weeks or≥4 weeks）,and lines of the chemotherapy received were assessed.Treatment related side effects were also assessed.Results：The median survival of combined group was longer（10.0 months）than that of HAP group（5.1 months）.One-year survival rate of combined treatment group and HAP group was 38.5%±9.5%and 33.3%±11.1%,respectively（P〉0.05）.One-year survival rate of those received more and less than 4-week treatment was 57.1%±18.7%and 8.3%±8.0%,respectively（P=0.001）.Conclusions：The study supports the safety and potential efficacy of HAP treatment in prevention of chemo-related side effects for stageⅣmetastatic gastric cancer treated with conventional chemotherapy.Further studies are needed to investigate and confirm the results before applying the treatment in clinical settings.
doi_str_mv 10.1007/s11655-012-1084-0
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_s11655_012_1084_0</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>50318866</cqvip_id><sourcerecordid>22610951</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-9821e673ecfa66665d48c1fd596e9aaafc8ecce12d8113d8903a011a7db161153</originalsourceid><addsrcrecordid>eNp9kE1OwzAQhS0EouXnAGyQOUBgxq6dZFlV0CIVUallwyZyHSdNlabFTop6AE7CzTgJrlK6ZDbzNDPvafQRcoNwjwDhg0OUQgSALECIegGckC7GMQ-gB-zUaxkyr1F0yIVzSwARShDnpMOYRIgFdsn7tLHbYqtK2q9UuXOFo-uMTmuVG_rz9U1fTK1crepC06EX1veBqrSxdOKHpqodnVmjapPSz6Je0JGq8v4qmJSNuyJnmSqduT70S_L29DgbjILx6_B50B8HmodQB3HE0MiQG50p6UukvUhjlopYmlgplenIaG2QpREiT6MYuAJEFaZzlIiCXxJsc7VdO2dNlmxssVJ2lyAke05JyynxnJI9pwS857b1bJr5yqRHxx8Yf8DaA-dXVW5sslw31iNy_6beHT5ZrKv8w_uOwQI4RpGU_BfJxX8Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Survival Analysis of Stage Ⅳ Metastatic Gastric Cancer Patients Treated with HangAm-Plus</title><source>Springer Link</source><creator>Park, Jae-Woo ; Yoon, Jeungwon ; Cho, Chong-Kwan ; Lee, Yeon-Weol ; Yoo, Hwa-Seung</creator><creatorcontrib>Park, Jae-Woo ; Yoon, Jeungwon ; Cho, Chong-Kwan ; Lee, Yeon-Weol ; Yoo, Hwa-Seung</creatorcontrib><description>Objective：To evaluate the efficacy of HangAm-Plus（HAP）on stageⅣmetastatic gastric cancer by analyzing the treated patients’overall survival outcome.Methods：Following the study eligibility,overall survival and one year survival rate of 44 stageⅣmetastatic gastric cancer patients who visited EastWest Cancer Center（EWCC）were analyzed.The study consisted of two arms：HAP treatment only（n=18）and combined treatment of concurrent conventional chemotherapy and HAP（n=26）.Patient characteristics by gender,age,surgical intervention,Eastern Cooperative Oncology Group（ECOG）score,treatment duration（〈4 weeks or≥4 weeks）,and lines of the chemotherapy received were assessed.Treatment related side effects were also assessed.Results：The median survival of combined group was longer（10.0 months）than that of HAP group（5.1 months）.One-year survival rate of combined treatment group and HAP group was 38.5%±9.5%and 33.3%±11.1%,respectively（P〉0.05）.One-year survival rate of those received more and less than 4-week treatment was 57.1%±18.7%and 8.3%±8.0%,respectively（P=0.001）.Conclusions：The study supports the safety and potential efficacy of HAP treatment in prevention of chemo-related side effects for stageⅣmetastatic gastric cancer treated with conventional chemotherapy.Further studies are needed to investigate and confirm the results before applying the treatment in clinical settings.</description><identifier>ISSN: 1672-0415</identifier><identifier>EISSN: 1993-0402</identifier><identifier>DOI: 10.1007/s11655-012-1084-0</identifier><identifier>PMID: 22610951</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Clinical Experience ; Drugs, Chinese Herbal - adverse effects ; Drugs, Chinese Herbal - therapeutic use ; Female ; HAP ; Humans ; Male ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - pathology ; Survival Analysis ; Young Adult ; 患者 ; 生存分析 ; 综合治疗 ; 联合治疗 ; 胃癌 ; 舞台 ; 转移性</subject><ispartof>Chinese journal of integrative medicine, 2014, Vol.20 (1), p.49-55</ispartof><rights>Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c370t-9821e673ecfa66665d48c1fd596e9aaafc8ecce12d8113d8903a011a7db161153</citedby><cites>FETCH-LOGICAL-c370t-9821e673ecfa66665d48c1fd596e9aaafc8ecce12d8113d8903a011a7db161153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/86437A/86437A.jpg</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22610951$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Jae-Woo</creatorcontrib><creatorcontrib>Yoon, Jeungwon</creatorcontrib><creatorcontrib>Cho, Chong-Kwan</creatorcontrib><creatorcontrib>Lee, Yeon-Weol</creatorcontrib><creatorcontrib>Yoo, Hwa-Seung</creatorcontrib><title>Survival Analysis of Stage Ⅳ Metastatic Gastric Cancer Patients Treated with HangAm-Plus</title><title>Chinese journal of integrative medicine</title><addtitle>Chin. J. Integr. Med</addtitle><addtitle>Chinese Journal of Integrative Medicine</addtitle><description>Objective：To evaluate the efficacy of HangAm-Plus（HAP）on stageⅣmetastatic gastric cancer by analyzing the treated patients’overall survival outcome.Methods：Following the study eligibility,overall survival and one year survival rate of 44 stageⅣmetastatic gastric cancer patients who visited EastWest Cancer Center（EWCC）were analyzed.The study consisted of two arms：HAP treatment only（n=18）and combined treatment of concurrent conventional chemotherapy and HAP（n=26）.Patient characteristics by gender,age,surgical intervention,Eastern Cooperative Oncology Group（ECOG）score,treatment duration（〈4 weeks or≥4 weeks）,and lines of the chemotherapy received were assessed.Treatment related side effects were also assessed.Results：The median survival of combined group was longer（10.0 months）than that of HAP group（5.1 months）.One-year survival rate of combined treatment group and HAP group was 38.5%±9.5%and 33.3%±11.1%,respectively（P〉0.05）.One-year survival rate of those received more and less than 4-week treatment was 57.1%±18.7%and 8.3%±8.0%,respectively（P=0.001）.Conclusions：The study supports the safety and potential efficacy of HAP treatment in prevention of chemo-related side effects for stageⅣmetastatic gastric cancer treated with conventional chemotherapy.Further studies are needed to investigate and confirm the results before applying the treatment in clinical settings.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Clinical Experience</subject><subject>Drugs, Chinese Herbal - adverse effects</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Female</subject><subject>HAP</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Staging</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - pathology</subject><subject>Survival Analysis</subject><subject>Young Adult</subject><subject>患者</subject><subject>生存分析</subject><subject>综合治疗</subject><subject>联合治疗</subject><subject>胃癌</subject><subject>舞台</subject><subject>转移性</subject><issn>1672-0415</issn><issn>1993-0402</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp9kE1OwzAQhS0EouXnAGyQOUBgxq6dZFlV0CIVUallwyZyHSdNlabFTop6AE7CzTgJrlK6ZDbzNDPvafQRcoNwjwDhg0OUQgSALECIegGckC7GMQ-gB-zUaxkyr1F0yIVzSwARShDnpMOYRIgFdsn7tLHbYqtK2q9UuXOFo-uMTmuVG_rz9U1fTK1crepC06EX1veBqrSxdOKHpqodnVmjapPSz6Je0JGq8v4qmJSNuyJnmSqduT70S_L29DgbjILx6_B50B8HmodQB3HE0MiQG50p6UukvUhjlopYmlgplenIaG2QpREiT6MYuAJEFaZzlIiCXxJsc7VdO2dNlmxssVJ2lyAke05JyynxnJI9pwS857b1bJr5yqRHxx8Yf8DaA-dXVW5sslw31iNy_6beHT5ZrKv8w_uOwQI4RpGU_BfJxX8Q</recordid><startdate>2014</startdate><enddate>2014</enddate><creator>Park, Jae-Woo</creator><creator>Yoon, Jeungwon</creator><creator>Cho, Chong-Kwan</creator><creator>Lee, Yeon-Weol</creator><creator>Yoo, Hwa-Seung</creator><general>Springer Berlin Heidelberg</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2014</creationdate><title>Survival Analysis of Stage Ⅳ Metastatic Gastric Cancer Patients Treated with HangAm-Plus</title><author>Park, Jae-Woo ; Yoon, Jeungwon ; Cho, Chong-Kwan ; Lee, Yeon-Weol ; Yoo, Hwa-Seung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-9821e673ecfa66665d48c1fd596e9aaafc8ecce12d8113d8903a011a7db161153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Clinical Experience</topic><topic>Drugs, Chinese Herbal - adverse effects</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Female</topic><topic>HAP</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Staging</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - pathology</topic><topic>Survival Analysis</topic><topic>Young Adult</topic><topic>患者</topic><topic>生存分析</topic><topic>综合治疗</topic><topic>联合治疗</topic><topic>胃癌</topic><topic>舞台</topic><topic>转移性</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Jae-Woo</creatorcontrib><creatorcontrib>Yoon, Jeungwon</creatorcontrib><creatorcontrib>Cho, Chong-Kwan</creatorcontrib><creatorcontrib>Lee, Yeon-Weol</creatorcontrib><creatorcontrib>Yoo, Hwa-Seung</creatorcontrib><collection>维普_期刊</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Chinese journal of integrative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Jae-Woo</au><au>Yoon, Jeungwon</au><au>Cho, Chong-Kwan</au><au>Lee, Yeon-Weol</au><au>Yoo, Hwa-Seung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival Analysis of Stage Ⅳ Metastatic Gastric Cancer Patients Treated with HangAm-Plus</atitle><jtitle>Chinese journal of integrative medicine</jtitle><stitle>Chin. J. Integr. Med</stitle><addtitle>Chinese Journal of Integrative Medicine</addtitle><date>2014</date><risdate>2014</risdate><volume>20</volume><issue>1</issue><spage>49</spage><epage>55</epage><pages>49-55</pages><issn>1672-0415</issn><eissn>1993-0402</eissn><abstract>Objective：To evaluate the efficacy of HangAm-Plus（HAP）on stageⅣmetastatic gastric cancer by analyzing the treated patients’overall survival outcome.Methods：Following the study eligibility,overall survival and one year survival rate of 44 stageⅣmetastatic gastric cancer patients who visited EastWest Cancer Center（EWCC）were analyzed.The study consisted of two arms：HAP treatment only（n=18）and combined treatment of concurrent conventional chemotherapy and HAP（n=26）.Patient characteristics by gender,age,surgical intervention,Eastern Cooperative Oncology Group（ECOG）score,treatment duration（〈4 weeks or≥4 weeks）,and lines of the chemotherapy received were assessed.Treatment related side effects were also assessed.Results：The median survival of combined group was longer（10.0 months）than that of HAP group（5.1 months）.One-year survival rate of combined treatment group and HAP group was 38.5%±9.5%and 33.3%±11.1%,respectively（P〉0.05）.One-year survival rate of those received more and less than 4-week treatment was 57.1%±18.7%and 8.3%±8.0%,respectively（P=0.001）.Conclusions：The study supports the safety and potential efficacy of HAP treatment in prevention of chemo-related side effects for stageⅣmetastatic gastric cancer treated with conventional chemotherapy.Further studies are needed to investigate and confirm the results before applying the treatment in clinical settings.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>22610951</pmid><doi>10.1007/s11655-012-1084-0</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1672-0415
ispartof Chinese journal of integrative medicine, 2014, Vol.20 (1), p.49-55
issn 1672-0415
1993-0402
language eng
recordid cdi_crossref_primary_10_1007_s11655_012_1084_0
source Springer Link
subjects Adult
Aged
Aged, 80 and over
Clinical Experience
Drugs, Chinese Herbal - adverse effects
Drugs, Chinese Herbal - therapeutic use
Female
HAP
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Survival Analysis
Young Adult
患者
生存分析
综合治疗
联合治疗
胃癌
舞台
转移性
title Survival Analysis of Stage Ⅳ Metastatic Gastric Cancer Patients Treated with HangAm-Plus
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T15%3A38%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20Analysis%20of%20Stage%20%E2%85%A3%20Metastatic%20Gastric%20Cancer%20Patients%20Treated%20with%20HangAm-Plus&rft.jtitle=Chinese%20journal%20of%20integrative%20medicine&rft.au=Park,%20Jae-Woo&rft.date=2014&rft.volume=20&rft.issue=1&rft.spage=49&rft.epage=55&rft.pages=49-55&rft.issn=1672-0415&rft.eissn=1993-0402&rft_id=info:doi/10.1007/s11655-012-1084-0&rft_dat=%3Cpubmed_cross%3E22610951%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c370t-9821e673ecfa66665d48c1fd596e9aaafc8ecce12d8113d8903a011a7db161153%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/22610951&rft_cqvip_id=50318866&rfr_iscdi=true